Grufity logoGrufity logo

Laboratory Corporation of America Holdings Stock Research

LH

229.42USD+4.72(+2.10%)Market Closed

Market Summary

USD229.42+4.72
Market Closed
2.10%

LH Alerts

LH Stock Price

LH RSI Chart

LH Valuation

Market Cap

20.6B

Price/Earnings (Trailing)

16.07

Price/Sales (Trailing)

1.38

Price/Free Cashflow

13.95

LH Price/Sales (Trailing)

LH Profitability

Operating Margin

29.48%

Return on Equity

12.67%

Return on Assets

6.35%

Free Cashflow Yield

7.17%

LH Fundamentals

LH Revenue

Revenue (TTM)

14.9B

Revenue Y/Y

-9.42%

Revenue Q/Q

1.89%

LH Earnings

Earnings (TTM)

1.3B

Earnings Y/Y

-86.24%

Earnings Q/Q

-78.43%

Price Action

52 Week Range

199.73278.31
(Low)(High)

Last 7 days

3.6%

Last 30 days

-6.1%

Last 90 days

-4.6%

Trailing 12 Months

-15.7%

LH Financial Health

Current Ratio

1.5

LH Investor Care

Buy Backs (1Y)

6.47%

Diluted EPS (TTM)

17.33

Peers (Alternatives to Laboratory Corporation of America Holdin)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
HCA
73.1B
60.2B
 6.57% 2.08%
12.96
1.21
 2.52% -18.88%
LH
20.6B
14.9B
 -6.12% -15.74%
16.07
1.38
 -7.72% -46.20%
DGX
16.4B
9.9B
 0.67% 1.77%
17.35
1.66
 -8.39% -52.58%
MID-CAP
CHE
8.0B
2.1B
 1.10% 3.71%
32.07
3.75
 -0.20% -7.05%
DVA
7.3B
11.6B
 -3.50% -30.75%
13.09
0.63
 -0.08% -42.73%
ACHC
6.5B
2.6B
 -1.74% 8.55%
23.78
2.49
 12.79% 43.28%
THC
6.2B
19.2B
 -1.59% -33.79%
6.21
0.32
 -1.60% -32.18%
EHC
5.4B
4.3B
 -6.00% -5.25%
19.8
1.23
 8.31% -34.26%
PGNY
2.9B
700.1M
 -16.69% -38.53%
96.17
4.17
 47.91% -53.84%
GH
2.4B
449.5M
 -25.80% -65.79%
-3.67
5.35
 20.31% -70.12%
SMALL-CAP
RDNT
1.3B
1.4B
 3.79% 9.33%
123.09
0.92
 8.74% -56.93%
HNGR
732.6M
1.2B
 0.48% -14.75%
19.64
0.62
 11.71% 25.50%
XGN
39.5M
45.4M
 -5.10% -69.75%
-0.98
0.87
 -5.93% -72.41%
AMS
17.3M
19.4M
 -20.38% 24.15%
11.77
0.89
 10.55% 123.93%
OTRK
14.0M
22.3M
 -16.26% -76.89%
-0.22
0.63
 -78.33% -207.64%

Financials for Laboratory Corporation of America Holdin

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-2.5%14,87715,25915,71515,85916,121
Cost Of Revenue0.2%10,49210,46810,59910,60110,497
Gross Profit-8.5%4,3854,7905,1165,2585,624
  S&GA Expenses-0.4%1,9972,0042,0141,9861,952
Interest Expenses3.6%180174170206212
Net Income-27.2%1,2791,7561,9912,0992,377
Net Income Margin-25.3%0.09*0.12*0.13*0.13*-
Free Cahsflow-0.8%1,4741,4861,8651,704-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets1.7%20,15519,82620,40320,72820,385
  Current Assets5.8%4,6254,3725,0315,2305,331
    Cash Equivalents4.9%4304101,0691,2341,473
  Inventory0.6%471468436441401
  Net PPE2.5%2,9562,8852,8702,8082,815
  Goodwill-1.2%8,1218,2188,1148,1667,959
Liabilities3.3%10,0409,7159,9829,98710,091
  Current Liabilities22.1%3,0792,5222,6432,6422,783
    LT Debt, Non Current-5.5%5,0395,3345,3605,3835,417
Shareholder's Equity0.0%10,09710,09210,40110,72110,273
  Retained Earnings-2.4%10,58210,84510,89810,94810,457
  Additional Paid-In CapitalNaN%--29.00--
Shares Outstanding-1.5%90.0091.0096.0093.00-
Cashflow (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-2.2%1,9562,0002,3932,3083,110
  Share Based Compensation-7.6%144156179163154
Cashflow From Investing-1.2%-1,652-1,633-1,477-1,325-884
Cashflow From Financing32.5%-1,322-1,958-1,787-1,633-2,065
  Dividend PaymentsInfinity%2600.00---
  Buy Backs-31.2%1,1001,600933800-

Risks for LH

What is the probability of a big loss on LH?

58.5%

Probability that Laboratory Corporation of America Holdin stock will be more than 20% underwater in next one year

37.7%

Probability that Laboratory Corporation of America Holdin stock will be more than 30% underwater in next one year.

19.2%

Probability that Laboratory Corporation of America Holdin stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does LH drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Laboratory Corporation of America Holdin was unfortunately bought at previous high price.

Drawdowns

Returns for LH

Cumulative Returns on LH

9.6%

10-Year Cumulative Returns

9.9%

7-Year Cumulative Returns

7.0%

5-Year Cumulative Returns

19.8%

3-Year Cumulative Returns

What are the long-term rolling returns for LH?

FIve years rolling returns for Laboratory Corporation of America Holdin.

Annualized Returns

Which funds bought or sold LH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-27
Neo Ivy Capital Management
added
5,331
1,183,000
1,202,000
 0.81%
2023-03-23
ETF MANAGERS GROUP, LLC
reduced
-37.02
-368,706
968,294
 0.04%
2023-03-23
MetLife Investment Management, LLC
reduced
-3.57
534,325
5,448,540
 0.04%
2023-03-17
American Portfolios Advisors
reduced
-15.05
-18,036
52,059
 -%
2023-03-15
B. Riley Wealth Advisors, Inc.
reduced
-11.29
14,458
819,458
 0.02%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-4.5
1,713,530
19,193,500
 0.02%
2023-03-08
SHEETS SMITH WEALTH MANAGEMENT
unchanged
-
108,361
829,361
 0.13%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-3.29
357,000
3,547,000
 0.02%
2023-03-03
TIAA, FSB
reduced
-10.35
20,730
701,730
 -%
2023-03-02
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA
new
-
93,957
93,957
 -%

1–10 of 49

Latest Funds Activity

Are funds buying LH calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own LH
No. of Funds

LH Alerts

Laboratory Corporation of America Holdin News

Schedule 13G FIlings of Laboratory Corporation of America Holdin

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
11.79%
10,450,115
SC 13G/A
Jan 26, 2023
blackrock inc.
13.0%
11,474,507
SC 13G/A
Jan 20, 2023
blackrock inc.
13.0%
11,474,507
SC 13G/A
Mar 09, 2022
blackrock inc.
10.4%
9,706,541
SC 13G/A
Feb 10, 2022
vanguard group inc
11.24%
10,753,065
SC 13G/A
Feb 01, 2022
blackrock inc.
8.6%
8,274,411
SC 13G/A
Feb 10, 2021
vanguard group inc
10.68%
10,405,602
SC 13G/A
Jan 29, 2021
blackrock inc.
8.0%
7,832,565
SC 13G/A
Feb 12, 2020
vanguard group inc
11.21%
10,891,852
SC 13G/A
Feb 05, 2020
blackrock inc.
9.1%
8,855,703
SC 13G/A

LH Fair Value

Laboratory Corporation of America Holdin fair value in different scenarios

The table shows the Fair Value estimates for Laboratory Corporation of America Holdin for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

-

-

-

-

-

-
Current Inflation

217.46

-5.21%

294.34

28.30%

382.65

66.79%

516.07

124.95%

648.75

182.78%
Very High Inflation

-

-

-

-

-

-

-

-

-

-

Historical Laboratory Corporation of America Holdin Fair Value Estimates

Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Laboratory Corporation of America Holdin

View All Filings
Date Filed Form Type Document
Mar 30, 2023
ARS
ARS
Mar 30, 2023
DEF 14A
DEF 14A
Mar 30, 2023
DEFA14A
DEFA14A
Mar 27, 2023
SC 13D
13D - Major Acquisition
Mar 06, 2023
4
Insider Trading
Feb 28, 2023
10-K
Annual Report
Feb 23, 2023
4
Insider Trading
Feb 16, 2023
8-K
Current Report
Feb 16, 2023
4
Insider Trading
Feb 14, 2023
4
Insider Trading

Latest Insider Trading transactions for LH

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-02
Summy Amy B.
sold (taxes)
-89,558
239
-374
evp, chief marketing officer
2023-03-02
Summy Amy B.
acquired
-
-
1,340
evp, chief marketing officer
2023-02-21
Kirchgraber Paul R
sold
-2,004,680
250
-8,000
ceo, covance drug development
2023-02-21
Kirchgraber Paul R
acquired
547,530
182
3,000
ceo, covance drug development
2023-02-14
Schroeder Mark S
sold
-76,517
247
-309
evp, president-diagnostics lab
2023-02-13
van der Vaart Sandra D
sold (taxes)
-19,354
248
-78.00
evp, chief legal officer
2023-02-13
BERBERIAN LANCE
sold (taxes)
-21,091
248
-85.00
evp, cio & cto
2023-02-13
Kirchgraber Paul R
sold (taxes)
-35,234
248
-142
ceo, covance drug development
2023-02-13
Schechter Adam H
sold (taxes)
-290,312
248
-1,170
president & ceo
2023-02-13
Caveney Brian J
sold (taxes)
-30,768
248
-124
evp, president of diagnostics

1–10 of 50

About Laboratory Corporation of America Holdin

Adam H. Schechter
www.labcorp.com
65535
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations. It offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.

LH Income Statement

2022-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Consolidated Statements of Operations [Abstract]   
Revenues$ 14,876.8$ 16,120.9$ 13,978.5
Cost of Revenue10,491.710,496.69,025.7
Gross profit4,385.15,624.34,952.8
Selling, general and administrative expenses1,996.61,952.11,729.3
Amortization of intangibles and other assets259.3369.6275.4
Goodwill and Intangible Asset Impairment271.50.0462.1
Restructuring and other special charges83.843.140.6
Operating income1,773.93,259.52,445.4
Interest expense(180.3)(212.1)(207.4)
Equity method income, net5.426.52.9
Investment income8.910.210.3
Other, net(25.3)42.5(32.1)
Earnings before income taxes1,582.63,126.62,219.1
Provision for income taxes302.0747.1662.1
Net earnings1,280.62,379.51,557.0
Less: Net earnings attributable to the noncontrolling interest(1.5)(2.2)(0.9)
Net earnings attributable to Laboratory Corporation of America Holdings$ 1,279.1$ 2,377.3$ 1,556.1

LH Balance Sheet

2022-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]  
Deferred Revenue, Revenue Recognized$ 330,500,000$ 319,400,000
Current assets:  
Cash and Cash Equivalents, at Carrying Value430,000,000.01,472,700,000
Accounts receivable, net2,222,000,0002,261,500,000
Unbilled Contracts Receivable795,400,000716,800,000
Supplies inventory470,600,000401,400,000
Prepaid expenses and other707,000,000.0478,100,000
Total current assets4,625,000,0005,330,500,000
Property, plant and equipment, net2,956,200,0002,815,400,000
Goodwill, net8,121,000,0007,958,900,000
Intangible assets, net3,946,900,0003,735,500,000
Joint venture partnerships and equity method investments65,700,00060,900,000
Deferred Income Tax Assets, Net7,600,00021,600,000
Other assets, net432,700,000462,600,000
Total assets20,155,100,00020,385,400,000
Current liabilities:  
Finance Lease, Liability, Current6,000,000.010,500,000
Accounts payable934,800,000621,300,000
Accrued expenses and other1,068,800,0001,404,100,000
Deferred Revenue, Current582,100,000558,500,000
Operating Lease, Liability, Current185,500,000187,000,000.0
Short-term borrowings and current portion of long-term debt301,300,0001,500,000
Total current liabilities3,078,500,0002,782,900,000
Long-term debt, less current portion5,038,800,0005,416,500,000
Total maturities, due beyond one year679,700,000642,500,000
Total maturities, due beyond one year83,600,00084,600,000
Deferred income taxes and other tax liabilities736,200,000762,900,000
Other liabilities422,800,000402,000,000.0
Total liabilities10,039,600,00010,091,400,000
Commitments and contingent liabilities
Noncontrolling interest18,900,00020,600,000
Shareholders’ equity  
Common stock, 88.2 and 93.1 shares outstanding at December 31, 2022 and 2021, respectively8,100,0008,500,000
Retained earnings10,581,700,00010,456,800,000
Accumulated other comprehensive loss(493,200,000)(191,900,000)
Total shareholders’ equity10,096,600,00010,273,400,000
Total liabilities and shareholders’ equity$ 20,155,100,000$ 20,385,400,000